American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
07
01
2019
accepted:
11
06
2019
pubmed:
15
6
2019
medline:
7
10
2020
entrez:
15
6
2019
Statut:
ppublish
Résumé
To describe the clinical and serologic manifestations of Sjögren's syndrome (SS) in ethnic groups of the US. This was a cross-sectional study of 648 patients with primary SS: 20 African American (AA), 164 American Indian (AI), 426 European American (EA), and 38 patients of other races evaluated in a multidisciplinary Sjögren's International Collaborative Clinical Alliance research clinic. AA subjects comprised 3.1% of the SS cohort, much lower than the percentage of AA in the state of Oklahoma (P = 3.01 × E - 05), the US (P = 2.24E - 13), or a systemic lupus erythematosus (SLE) cohort at the same institution (P = 4.26 × 10E - 27). In contrast, the percentage of AI in the SS cohort (25.3%) was much higher than expected (P = 3.17E - 09 versus SLE cohort, P = 6.36 - 26 versus Oklahoma, and P = 8.14E - 96 versus US population). The SS classification criteria were similar between AA and EA, but subjects of AI ancestry had lower rates of abnormal tear and salivary flow, as well as anti-Ro/SSA and anti-La/SSB antibodies. Paradoxically, AI had higher levels of disease activity (mean ± SD European League Against Rheumatism Sjögren's Syndrome Disease Activity Index score 3.77 ± 4.78) in comparison to EA (2.90 ± 4.12; P = 0.011) and more extraglandular manifestations affecting mainly the articular and glandular domains. Meanwhile, AA patients were characterized by higher rates of hypergammaglobulinemia (odds ratio [OR] 1.39 [95% confidence interval (95% CI) 1.39-8.65]; P = 0.01), elevated erythrocyte sedimentation rate (ESR) (OR 3.95 [95% CI 1.46-9.95]; P = 0.009), and parotid enlargement (OR 4.40 [95% CI 1.49-13.07]; P = 0.02). AI are affected at high rates with SS but present with few classical features, potentially preventing timely diagnosis. In contrast to SLE, SS is infrequent and not more severe among AA, but the triad of hypergammaglobulinemia, increased ESR, and parotid enlargement warrants extra vigilance for lymphomagenesis.
Identifiants
pubmed: 31199565
doi: 10.1002/acr.24003
pmc: PMC6911033
mid: NIHMS1036097
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1049-1056Subventions
Organisme : NIDCR NIH HHS
ID : R01 DE015223
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE018209
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR053483
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR065953
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR073750
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI024717
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI024717
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI118787
Pays : United States
Organisme : NIDCR NIH HHS
ID : R21 DE021854
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR020143
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082714
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103510
Pays : United States
Organisme : NIAMS NIH HHS
ID : P50 AR060804
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144292
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR050782
Pays : United States
Organisme : BLRD VA
ID : I01 BX001451
Pays : United States
Informations de copyright
© 2019, American College of Rheumatology.
Références
Semin Arthritis Rheum. 2017 Apr;46(5):665-674
pubmed: 28012565
Arthritis Rheum. 1994 Aug;37(8):1158-65
pubmed: 8053953
RMD Open. 2015 Feb 20;1(1):e000022
pubmed: 26509054
Arch Ophthalmol. 1969 Jul;82(1):10-4
pubmed: 4183019
Am J Ophthalmol. 2010 Mar;149(3):405-15
pubmed: 20035924
Rheumatology (Oxford). 2016 Jul;55(7):1195-201
pubmed: 26998859
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
J Rheumatol Suppl. 1997 Sep;50:8-11
pubmed: 9292828
Ann Rheum Dis. 2011 Jun;70(6):968-72
pubmed: 21345815
J Rheumatol. 1993 Apr;20(4):618-22
pubmed: 8496853
Best Pract Res Clin Rheumatol. 2002 Dec;16(5):847-58
pubmed: 12473278
Semin Arthritis Rheum. 2010 Feb;39(4):257-68
pubmed: 19136143
Lupus. 2006;15(5):308-18
pubmed: 16761508
MMWR Suppl. 2013 Nov 22;62(3):184-6
pubmed: 24264513
Scand J Rheumatol. 2011 May;40(3):221-4
pubmed: 21231797
Arthritis Care Res (Hoboken). 2017 Oct;69(10):1612-1616
pubmed: 27998024
MMWR Suppl. 2013 Nov 22;62(3):3-5
pubmed: 24264483
Arthritis Rheum. 1990 Jan;33(1):37-48
pubmed: 2302266
Ann Rheum Dis. 2015 Nov;74(11):1983-9
pubmed: 24938285
Blood. 2013 Dec 12;122(25):4068-76
pubmed: 24159176
J Rheumatol. 2012 Oct;39(10):1934-41
pubmed: 22896022
Ann Rheum Dis. 2011 Aug;70(8):1363-8
pubmed: 21715359
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Ann Rheum Dis. 2017 Jun;76(6):1042-1050
pubmed: 27899373
Arthritis Care Res (Hoboken). 2014 Mar;66(3):454-63
pubmed: 23983119
Ann Rheum Dis. 2017 Jan;76(1):9-16
pubmed: 27789466
N Engl J Med. 2018 Mar 08;378(10):931-939
pubmed: 29514034
PLoS One. 2015 Feb 27;10(2):e0116189
pubmed: 25723713
J Autoimmun. 2015 Sep;63:47-58
pubmed: 26183766
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
Arthritis Rheum. 2008 Jan;58(1):15-25
pubmed: 18163481
Ann Rheum Dis. 2014 Jan;73(1):31-8
pubmed: 23968620
Arthritis Rheum. 2007 May 15;57(4):576-84
pubmed: 17471524
Arthritis Rheumatol. 2017 Jan;69(1):35-45
pubmed: 27785888
Curr Opin Rheumatol. 2014 Sep;26(5):520-7
pubmed: 25050925
Semin Arthritis Rheum. 2017 Apr;46(5):675-686
pubmed: 27914688
Semin Arthritis Rheum. 2018 Feb;47(4):586-592
pubmed: 28823732
J Oral Pathol Med. 2001 Jan;30(1):1-6
pubmed: 11140894
Ann Rheum Dis. 2010 Jun;69(6):1103-9
pubmed: 19561361